New automated VPT systems for topical drug performance testing

11 Jan 2018

The MedStat-HT and MedFlux-HT help to de-risk development programs and shorten development timelines.

MedPharm has launched two automated testing services, MedStat-HT and MedFlux-HT to de-risk clients' development programs and shorten development timelines. Both pieces of equipment incorporate design features that provide significant improvements over commercially available systems.

New automated VPT systems for topical drug performance testing
MedPharm's US labs in Research Triangle Park, NC.

MedFlux-HT is an automated system of 32 flow-through diffusion cells for measuring the in vitro permeation and penetration of drugs into and through human skin (IVPT). It can also be set up with other tissues determined by the medicine’s target site (e.g., mucosal, buccal, etc.). The system has been uniquely designed to provide local clearance of the tissue to mimic the clinical setting and to maximise sink conditions without the addition of solvents when studying lipophilic compounds in static cells.

Another key design improvement is the use of a high-throughput collection enabling reduction in sample collection, set-up time, and processing which can be further coupled with liquid handlers and automated sample managers. MedPharm use MedFlux-HT® as a key tool in topical formulation development, and optimisation. Significant benefits of this new system include reduction in sample variation, system artefacts, and experimental time to further de-risk topical formulation development prior to clinical trials. The use of MedFlux-HT has been important in the support of patent claims, substantiation of marketing claims for OTC products, new chemical entity development, and development of generic products.

MedStat-HT is an automated system of 24 vertical diffusion cells (VDC) more commonly known as ‘Franz’ or ‘static’ cells for measuring the in vitro release of drug from topical medicines across synthetic membranes (IVRT). Unique design features along with automated collection provide significant reduction in variation associated with sampling and fluidics compared with manually operated VDC systems. The key benefits of the new system are its ability to better characterise formulation drug release properties for potential patent claim support (formulation optimisation and comparison, and potential product quality and stability specifications) with a reduction in experimental time and less variability.

"MedPharm is continuing to develop innovative solutions to help our clients further de-risk their topical development programs and reduce development timelines," commented Jon Lenn, MedPharm’s Vice President of US Operations. He added: "MedStat-HT and MedFlux-HT greatly improve the efficiency of data collection and decrease variations seen with conventional systems for IVRT and IVPT, so clients and their investors gain confidence in the data generated and ultimately get to the market sooner."

Read More

Related news

SIRIO Pharma opens multimillion gummy production plant

SIRIO Pharma opens multimillion gummy production plant

18 Oct 2018

The new ‘Centre of Excellence’ already boasts one of the world’s most advanced gummy production line designed to meet demand from global markets.

Read more 
New formulation modelling successes using ex vivo tissue

New formulation modelling successes using ex vivo tissue

9 Oct 2018

One study uses the company's proprietary TurChub model, to evaluate the diffusion and subsequent activity of drugs in human nails.

Read more 
Three-way collaboration to advance gene therapy

Three-way collaboration to advance gene therapy

4 Oct 2018

Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.

Read more 
New oral treatment for metastatic melanoma receives EU authorisation

New oral treatment for metastatic melanoma receives EU authorisation

24 Sep 2018

Encorafenib in combination with binimetinib demonstrated 14.9 months median progression-free survival compared with vemurafenib monotherapy (7.3 months).

Read more 
Plasticell wins military contract to develop regenerative medicines for the battlefield

Plasticell wins military contract to develop regenerative medicines for the battlefield

4 Sep 2018

Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.

Read more 
New biopharmaceutical testing laboratory to open in Geneva

New biopharmaceutical testing laboratory to open in Geneva

28 Aug 2018

SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.

Read more 
Exosome isolation manufacturing and characterization

Exosome isolation manufacturing and characterization

13 Aug 2018

New service to reliably and reproducibly isolate exosomes from almost any biofluid.

Read more 
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Read more 
A new era for migraine patients

A new era for migraine patients

6 Aug 2018

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Read more 
WuXi STA and Antengene sign development and manufacturing agreement

WuXi STA and Antengene sign development and manufacturing agreement

24 Jul 2018

WuXi STA chosen for its end-to-end CMC platform for new drug development.

Read more